Question 1

What specific benefits do you think I might gain from participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma clinical trial (NCT02921022). Contact the study team or your healthcare provider for specific answers.

What this study is about